News

  • 26 March 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimumcontact force (CF), as well as minimum Force Time Integral (FTI™), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF). Published in the April 2013 issue of the American Heart Association journal Circulation: Arrhythmia and Electrophysiology, the newly created guidelines call for a CF target of 20 g (and minimum CF of 10 g) and minimum FTI of 400 gs per individual ablation lesion.

  • 22 March 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today its decision to withdraw, for strategic reasons, the Marketing Authorization Application (MAA) for Raxone® as a potential therapy for Leber's Hereditary Optic Neuropathy (LHON). Santhera now plans to file a new application based on emerging clinical evidence supporting the efficacy of Raxone® in the treatment of LHON. This strategy is expected to increase the probability of a successful MAA outcome and is contingent on the availability of sufficient financial resources or on the outcome of ongoing licensing and M&A discussions.

  • 13 March 2013

    Sequana Medical is pleased to announce that Prof. Giorgio Enrico Gerunda from the University of Modena and Reggio Emilia has implanted Italy’s first two patients with the alfapump system. The alfapump system is a fully implantable battery-powered pump that is designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from advanced liver disease. 

  • 5 March 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner. This second successful closing brings the total in series C funds raised to USD 44.6 million/CHF 41.4 million.

  • 28 February 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today that following the voluntary withdrawal of Catena® from the Canadian market and the earlier negative decision of the Committee for Medicinal Products for Human Use (CHMP) on the Market Authorization Application for Raxone® in Leber's Hereditary Optic Neuropathy (LHON), the Board has decided to consider strategic options including product licensing for Raxone® in LHON and the possibility of a merger or acquisition. Santhera has already received expressions of interest from third parties and has retained Piper Jaffray Limitedto assist the Company in this process.